Skip to main content
Episurf logo

Episurf — Investor Relations & Filings

Ticker · EPIS ISIN · SE0003491562 LEI · 549300GORBCSMHZB2J75 ST Manufacturing
Open in API
Filings indexed 875 across all filing types
Latest filing 2017-06-12 Regulatory Filings
Country SE Sweden
Listing ST EPIS

About Episurf

https://episurf.com/

Episurf is a medical device company that develops and commercializes patient-specific solutions for treating painful joint injuries. The company's core technology utilizes 3D imaging to create personalized orthopedic implants and surgical instruments tailored to each patient's unique anatomy and cartilage defect. Its primary product line, the Episealer® system, provides minimally invasive implants for treating cartilage and underlying bone lesions in the knee and ankle joints. The objective of this individualized approach is to repair the joint, alleviate pain, and restore function, offering a treatment option for patients, often middle-aged, who are not yet candidates for total joint replacement surgery.

Recent filings

Filing Released Lang Actions
Episurf Medical obtains further granted patent in Europe
Regulatory Filings Classification · 95% confidence The document is a short announcement (1756 characters) detailing that Episurf Medical has obtained a granted patent in Europe for a specific surgical tool. It includes quotes from the CEO and standard company boilerplate information. It does not appear to be a full financial report (like 10-K or IR), a management discussion (MDA), or a formal regulatory filing like a Director's Dealing (DIRS) or Major Shareholding (MRQ). Since it is an announcement regarding a specific, non-financial corporate event (patent grant) that doesn't fit the other specific categories (like M&A, Capital Change, Dividend), it falls best under the general 'Regulatory Filings' or 'Miscellaneous' category, which is RNS, as per the definitions provided, especially since it mentions compliance with the EU Market Abuse Regulation.
2017-06-12 English
Episurf Medical erhåller ytterligare beviljat patent i Europa
Regulatory Filings Classification · 95% confidence The document is a short announcement in Swedish regarding Episurf Medical receiving an additional granted patent in Europe for a surgical instrument related to their Episealer implant. It includes a quote from the CEO and contact information. Crucially, the final paragraph states: "Denna information är sådan information som Episurf Medical AB är skyldigt att offentliggöra enligt EU:s marknadsmissbruksförordning" (This information is such information that Episurf Medical AB is obliged to disclose pursuant to the EU's Market Abuse Regulation). This indicates a mandatory regulatory disclosure that is not a standard periodic report (like 10-K or IR) or a specific corporate action like dividend or management change. Since it is a general regulatory announcement concerning intellectual property/product development that doesn't fit the specific categories (like LTR for legal proceedings or CAP for financing), the most appropriate fallback category is Regulatory Filings (RNS). The document length is very short (1723 chars), confirming it is an announcement, not a full report.
2017-06-12 Swedish
Episurf Medical appoints Dr Michael Manley special advisor for US strategy
Board/Management Information Classification · 99% confidence The document announces the appointment of Dr. Michael Manley as a special advisor to support the company's US strategy. This involves a change in senior advisory personnel. Based on the provided definitions, the category 'Board/Management Information (Code: MANG)' covers announcements of changes in the company's board of directors or senior management. The document is a direct announcement of a key personnel addition, fitting the MANG definition perfectly. The document length is short (2315 chars), but it is the primary announcement itself, not an announcement *about* another report, so RPA/RNS is not the primary classification.
2017-06-07 English
Episurf Medical utser Dr Michael Manley till speciell strategisk rådgivare för USA strategin
Board/Management Information Classification · 99% confidence The document announces the appointment of Dr. Michael Manley as a special strategic advisor to support the company's US market strategy. This involves a change in senior advisory personnel. Reviewing the definitions, the 'Board/Management Information (Code: MANG)' category covers 'Announcement of changes in the company's board of directors or senior management.' This announcement fits perfectly under this definition as it details the appointment of a key strategic advisor, which falls under senior management/advisory changes. The document is short and is an announcement, not a comprehensive report.
2017-06-07 Swedish
Episurf Medicals styrelse utser Pål Ryfors till vd och koncernchef samt utser ny finanschef
Board/Management Information Classification · 99% confidence The document text is an announcement detailing the appointment of Pål Ryfors as CEO and the appointment of Veronica Wallin as CFO for Episurf Medical. This directly relates to changes in the company's senior management team. Based on the provided definitions, the category 'Board/Management Information' (Code: MANG) is the most appropriate classification for announcements regarding changes in senior management.
2017-06-02 Swedish
Episurf Medical's Board names Pål Ryfors new CEO and appoints new CFO
Board/Management Information Classification · 99% confidence The document explicitly announces the appointment of a new CEO (Pål Ryfors) and a new CFO (Veronica Wallin) by the Board of Directors. This content directly aligns with the definition of 'Board/Management Information' (MANG), which covers announcements of changes in senior management.
2017-06-02 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.